Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1995 May-Jun;2(3):526-30.
doi: 10.1016/1071-5576(94)00058-9.

Human placental transfer of the prostaglandin inhibitor sulindac using an in vitro model

K Higby  1 , B Elliott, T S King, D Frasier, O Langer
Affiliations

Human placental transfer of the prostaglandin inhibitor sulindac using an in vitro model

K Higby et al. J Soc Gynecol Investig. 1995 May-Jun.

Abstract

Objective: We determined whether the prostaglandin inhibitor sulindac crosses the human placenta.

Methods: The recirculating single-cotyledon placenta model was used to characterize the maternal-to-fetal and fetal-to-maternal transport of 14C-labeled sulindac in normal term placentas perfused immediately after delivery. Antipyrine was added as a standard for simple diffusion. Serial samples were taken from both reservoirs during each 3-hour perfusion. Transport was calculated using liquid scintillation spectrometry for 14C-labeled sulindac and high-performance liquid chromatography for antipyrine.

Results: There was significant maternal-to-fetal transfer of sulindac. The mean (+/- SD) transfer at 2 hours was 7.22 +/- 2.57%. The fetal-to-maternal transfer was similar at 10.75 +/- 3.80%. The mean maternal/fetal concentration ratio of sulindac was 0.42 at 3 hours. Placental uptake ranged from 24-45 ng/g of placenta.

Conclusions: Sulindac crosses the human placenta in small but significant amounts. The transport is similar in both directions, implying simple diffusion.

PubMed Disclaimer